PT  - JOURNAL ARTICLE
ED  - ,
TI  - Safety update: dupilumab and ocular adverse reactions
AID  - 10.1136/dtb.2022.000073
DP  - 2023 Jan 01
TA  - Drug and Therapeutics Bulletin
PG  - 6--6
VI  - 61
IP  - 1
4099  - http://dtb.bmj.com/content/61/1/6.short
4100  - http://dtb.bmj.com/content/61/1/6.full
SO  - Drug Ther Bull2023 Jan 01; 61
AB  - Overview of: Medicines and Healthcare products Regulatory Agency. Dupilumab (Dupixent▼): risk of ocular adverse reactions and need for prompt management. Drug Safety Update 2022;16(4): 1.